Global biotechnology company Nona Biosciences, a wholly owned subsidiary of HBM Holding Limited (HKEX:02142), announced on Wednesday a research collaboration with the Medical University of Vienna (MedUni Vienna).

The collaboration enables the inter-university Ignaz Semmelweis Institute to leverage Nona's proprietary H2L2 Harbour Mice platform for generating fully human antibodies to support a range of research and development programs for infectious diseases.

Nona's H2L2 Harbour Mice technology is based on genetically modified mice that, following immunisation, produce antibodies with fully human structures. This enables fully human antibody candidates to be obtained and developed for further scientific investigation and potential medical applications.

Under the agreement, MedUni Vienna has been granted the right to use Nona's technology for antibody generation and to further develop the resulting antibodies and antibody products for research, diagnostic, and therapeutic applications. The H2L2 Harbour Mice platform and all associated intellectual property rights remain vested in Nona Biosciences.